Skip to main content
TipRanks
Go Ultimate75% OFF

Tryptamine Therapeutics (ENP) Share Price & Analysis

19 Followers

ENP Stock Chart & Stats

A$0.03A$0.00(0.00%)
At close: 4:00 PM GMT+11
AU$0.03AU$0.035AU$0.04Aug 26Sep 7Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
AUD 0.03 - AUD 0.03
52-Week Range
AUD 0.03 - AUD 0.04
Previous Close
AUD 0.03
Volume
N/A
Average Volume (3M)
1.20M
Market Cap
AUD 45.76M
Enterprise Value
AUD 48.24M
Total Cash (Recent Filing)
AUD 5.58M
Total Debt (Recent Filing)
AUD 0
Price to Earnings (P/E)
―
Beta
0.43
Next Earnings
Feb 26, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance Sheet

Positive equity and the absence of reported debt in recent annual reports reduce refinancing and interest-rate exposure. This gives the company greater financial flexibility than a similarly loss-making biotech, although ongoing losses still make preservation of that balance-sheet strength important.

Improved 2026 Performance

The improvement in annual net loss and the sharp reduction in operating and free cash outflows during 2026 indicate some cost containment. If sustained, this could extend the company’s operating runway and moderate the pace at which additional funding may be required.

Therapeutic Development Pipeline

Advancing multiple candidate programs through preclinical and clinical development creates potential for future product value beyond the company’s current financial profile. Success remains uncertain, but the therapeutic focus provides a defined platform for longer-term development and commercialization efforts.

Bears Say

No Meaningful Recurring Revenue

The absence of meaningful recurring revenue leaves the company dependent on development progress and external capital rather than operating sales. This weakens financial visibility over the next several quarters and means future research spending is not yet supported by a commercial revenue base.

Persistent Cash Burn

Consistently negative operating and free cash flow show that reported losses translate into actual cash consumption rather than being mainly non-cash accounting charges. Continued burn can reduce financial flexibility and require the company to manage spending carefully as programs advance.

Funding And Dilution Risk

Persistent losses and cash outflows increase the likelihood that additional external funding will be needed to sustain development. The history of debt in earlier years also shows that financing conditions can change, while new equity funding could dilute existing shareholders if losses persist.

Tryptamine Therapeutics News

ENP FAQ

What was Tryptamine Therapeutics’s price range in the past 12 months?
Tryptamine Therapeutics lowest share price was AU$0.03 and its highest was AU$0.04 in the past 12 months.
What is Tryptamine Therapeutics’s market cap?
Tryptamine Therapeutics’s market cap is AU$45.76M.
When is Tryptamine Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Tryptamine Therapeutics’s earnings last quarter?
Tryptamine Therapeutics released its earnings results on Aug 27, 2026. The company reported -AU$0.001 earnings per share for the quarter.
Is Tryptamine Therapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Tryptamine Therapeutics pay dividends?
Tryptamine Therapeutics does not currently pay dividends.
What is Tryptamine Therapeutics’s EPS estimate?
Tryptamine Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tryptamine Therapeutics have?
Tryptamine Therapeutics has 1,634,217,200 shares outstanding.
What happened to Tryptamine Therapeutics’s price movement after its last earnings report?
Tryptamine Therapeutics reported an EPS of -AU$0.001 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Tryptamine Therapeutics?
Currently, no hedge funds are holding shares in AU:ENP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology